The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide derivatives and to their use in therapy, particularly for the treatment of obesity or nicotine dependence.
The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide derivatives and to their use in therapy, particularly for the treatment of obesity or nicotine dependence.
The discovery of novel indole-2-carboxamides as cannabinoid CB1 receptor antagonists
作者:Phillip M. Cowley、James Baker、David R. Barn、Kirsteen I. Buchanan、Ian Carlyle、John K. Clark、Thomas R. Clarkson、Maureen Deehan、Darren Edwards、Richard R. Goodwin、David Jaap、Yasuko Kiyoi、Chris Mort、Ronald Palin、Alan Prosser、Glenn Walker、Nick Ward、Grant Wishart、Trevor Young
DOI:10.1016/j.bmcl.2010.10.104
日期:2011.1
The discovery and structure-activity relationship of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB1 receptor is disclosed. Compound 26i was found to be a high potency, selective cannabinoid CB1 antagonist. (C) 2010 Elsevier Ltd. All rights reserved.